Clinical Trials
13 trialsNCT07214662 2026-06-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Genentech, Inc.
Phase 1 Recruiting
NCT04930991 2026-06-01
OU202005AJ
University of Oklahoma
Phase EARLY_PHASE1 Terminated
NCT05646862 2026-05-06
INAVO121
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04337580 2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT06378398 2026-03-13
A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
NCT06510010 2026-01-26
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT02950259 2025-12-03
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Providence Health & Services
Phase 1 Completed
NCT05680870 2025-09-09
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
Tanta University
Phase 3 Completed
NCT06383338 2025-09-08
PEGASUS
Murdoch Childrens Research Institute
Phase 1 Recruiting
NCT05487235 2025-07-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06150898 2025-06-13
KePreSt
Jules Bordet Institute
Phase 2 Recruiting